232 related articles for article (PubMed ID: 38201238)
21. Overcoming Chemotherapy Resistance in Metastatic Cancer: A Comprehensive Review.
Eslami M; Memarsadeghi O; Davarpanah A; Arti A; Nayernia K; Behnam B
Biomedicines; 2024 Jan; 12(1):. PubMed ID: 38255288
[TBL] [Abstract][Full Text] [Related]
22. Recent advances in immunotherapies against infectious diseases.
Ramamurthy D; Nundalall T; Cingo S; Mungra N; Karaan M; Naran K; Barth S
Immunother Adv; 2021 Jan; 1(1):ltaa007. PubMed ID: 38626281
[TBL] [Abstract][Full Text] [Related]
23. Future Challenges in Cancer Resistance to Immunotherapy.
van Elsas MJ; van Hall T; van der Burg SH
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32290124
[TBL] [Abstract][Full Text] [Related]
24. The evolving immunotherapeutic landscape in advanced oesophagogastric cancer.
Flynn M; Young K; Cunningham D; Starling N
Ther Adv Med Oncol; 2018; 10():1758835918786228. PubMed ID: 30034550
[TBL] [Abstract][Full Text] [Related]
25. Roles of reactive oxygen species in inflammation and cancer.
Yu Y; Liu S; Yang L; Song P; Liu Z; Liu X; Yan X; Dong Q
MedComm (2020); 2024 Apr; 5(4):e519. PubMed ID: 38576456
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option?
Amin A; White RL
J Kidney Cancer VHL; 2014; 1(7):74-83. PubMed ID: 28326252
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic challenges in advanced renal cell carcinoma.
Cho DC
Clin Pract (Lond); 2013 Jan; 10(1):39-46. PubMed ID: 23378893
[TBL] [Abstract][Full Text] [Related]
28. Imaging techniques as predictive and prognostic biomarkers in renal cell carcinoma.
Nathan P; Vinayan A
Ther Adv Med Oncol; 2013 Mar; 5(2):119-31. PubMed ID: 23450112
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy combinations transform the treatment paradigm for advanced renal cell carcinoma.
Shaya JA; McKay RR
Ann Transl Med; 2019 Dec; 7(Suppl 8):S385. PubMed ID: 32016103
[No Abstract] [Full Text] [Related]
30. Bioinformatics analysis and experimental verification of the cancer-promoting effect of DHODH in clear cell renal cell carcinoma.
Wang S; Li Y; Lin Y; Li J; Guo L; Wang H; Lin X; Liu Z; Zhang B; Liao Z; Zhang Z
Sci Rep; 2024 May; 14(1):11985. PubMed ID: 38796629
[TBL] [Abstract][Full Text] [Related]
31. Teaching an Old Drug a New Trick: Targeting Treatment Resistance in Genitourinary Cancers.
Aguilar K; Sharma AK; Yang T; Mehta D; Panda CS; Lokeshwar VB
J Cell Signal; 2024; 5(2):51-56. PubMed ID: 38726221
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and toxicity of immune checkpoint inhibitors combination therapy for advanced renal cell carcinoma: a systematic review and network meta-analysis.
Chen X; Xu Z; Wu C; Xie L; Wang P; Liu X
Front Immunol; 2024; 15():1255577. PubMed ID: 38390328
[TBL] [Abstract][Full Text] [Related]
33. Immune checkpoint inhibitor-based therapy for advanced clear cell renal cell carcinoma: A narrative review.
Liu YF; Zhang ZC; Wang SY; Fu SQ; Cheng XF; Chen R; Sun T
Int Immunopharmacol; 2022 Sep; 110():108900. PubMed ID: 35753122
[TBL] [Abstract][Full Text] [Related]
34. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
35. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.
Lalani AA; McGregor BA; Albiges L; Choueiri TK; Motzer R; Powles T; Wood C; Bex A
Eur Urol; 2019 Jan; 75(1):100-110. PubMed ID: 30327274
[TBL] [Abstract][Full Text] [Related]
36. The State of Immunotherapy in Hepatobiliary Cancers.
Ilyas FZ; Beane JD; Pawlik TM
Cells; 2021 Aug; 10(8):. PubMed ID: 34440865
[TBL] [Abstract][Full Text] [Related]
37. Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma.
Meng L; Collier KA; Wang P; Li Z; Monk P; Mortazavi A; Hu Z; Spakowicz D; Zheng L; Yang Y
Cells; 2023 Dec; 13(1):. PubMed ID: 38201238
[TBL] [Abstract][Full Text] [Related]
38. Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma.
Jang A; Lichterman JN; Zhong JY; Shoag JE; Garcia JA; Zhang T; Barata PC
Hum Vaccin Immunother; 2023 Dec; 19(3):2276629. PubMed ID: 37947202
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
